Neurogene (NGNE) Research & Development (2013 - 2026)
Neurogene's (NGNE) quarterly Research & Development came in at $25.2 million in Q1 2026, up 41.61% YoY from $17.8 million in Q1 2025, and up 21.86% on a QoQ basis from $20.6 million in Q4 2025.
Neurogene (NGNE) Research & Development (2013 - 2026) Analysis & Trends
Neurogene (NGNE) has 14 years of Research & Development data on file, last reported at $25.2 million in Q1 2026.
- Quarterly Research & Development rose 41.61% year-over-year to $25.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $82.4 million (up 26.5% YoY) and the FY2025 annual result came in at $75.0 million, up 23.14% from the prior year.
- Research & Development grew to $25.2 million in Q1 2026, from $20.6 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $25.2 million in Q1 2026 to a low of $9.5 million in Q3 2022.
- A 5-year average of $14.9 million and a median of $15.3 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development jumped 67.8% — and 2023, when it dropped 25.6%.
- Tracing NGNE's Research & Development over 5 years: stood at $16.4 million in 2022, then dropped by 25.6% to $12.2 million in 2023, then grew by 25.96% to $15.3 million in 2024, then jumped by 34.48% to $20.6 million in 2025, then increased by 21.86% to $25.2 million in 2026.
- The last three Research & Development figures came in at $25.2 million (Q1 2026), $20.6 million (Q4 2025), and $17.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Neurogene | 815.03 Mn | 815.03 Mn | - | 25.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.47 Mn |
| Mar 31, 2026 | 25.15 Mn |
| Dec 31, 2025 | 20.64 Mn |
| Sep 30, 2025 | 17.24 Mn |
| Jun 30, 2025 | 19.37 Mn |
| Mar 31, 2025 | 17.76 Mn |
| Dec 31, 2024 | 15.35 Mn |
| Sep 30, 2024 | 16.29 Mn |
| Jun 30, 2024 | 15.74 Mn |
| Mar 31, 2024 | 13.54 Mn |
| Dec 31, 2023 | 12.18 Mn |
| Sep 30, 2023 | 11.61 Mn |
| Jun 30, 2023 | 10.32 Mn |
| Mar 31, 2023 | 10.28 Mn |
| Dec 31, 2022 | 16.38 Mn |
| Sep 30, 2022 | 9.47 Mn |
| Jun 30, 2022 | 10.96 Mn |
| Mar 31, 2022 | 10.70 Mn |
| Dec 31, 2021 | 9.76 Mn |
| Sep 30, 2021 | 9.90 Mn |